8 completed, 5 active not recruiting, 1 recruiting. 13 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 7, Active not recruiting 5, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Catherine Bollard: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 HST-NEETs, Bone Marrow Transplant - HIV Associated Lymphoma | Phase 2 | Completed | Catherine Bollard | 12 | 2021-10-25 | 2026-06-29 |
| Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) BM-MSC - Congenital Heart Disease (CHD) | Phase 1 | Active not recruiting | Catherine Bollard | 17 | 2020-07-29 | 2026-06-02 |
| Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST) DD HST-NEETs - HIV-Infected Individuals | Phase 1 | Active not recruiting | Catherine Bollard | 8 | 2020-05-01 | 2026-08-14 |
| Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma TAA-T cells, Nivolumab - Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Active not recruiting | Catherine Bollard | 18 | 2019-06-24 | 2026-08-14 |
| HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals HST-NEETs - HIV Infections | Phase 1 | Completed | Catherine Bollard | 7 | 2019-03-21 | 2025-04-29 |
| Multi-antigen T Cell Infusion Against Neuro-oncologic Disease TAA-T - Brain Tumor | Phase 1 | Active not recruiting | Catherine Bollard | 33 | 2018-12-12 | 2026-08-14 |
| Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease Allogeneic bone marrow-derived mesenchymal stromal cells - Inflammatory Bowel Diseases | Phase 1 | Completed | Catherine Bollard | 1 | 2018-06-07 | 2024-05-06 |
| Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis CMV/AdV /EBV/BKV specific T cells - Viral Infection | Phase 1 / Phase 2 | Active not recruiting | Catherine Bollard | 2 | 2018-01-24 | 2026-08-14 |
| Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies Tumor associated antigen lymphocytes (TAA-T) - Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS | Phase 1 | Recruiting | Catherine Bollard | 50 | 2015-04-02 | 2026-08-14 |
| Haploidentical Hematopoietic Stem Cell Transplantation peripheral blood stem cell graft that are CD34+ selected - Sickle Cell-thalassemia Disease, Thalassemia | Phase 1 | Completed | Catherine Bollard | 7 | 2015-01-01 | 2024-12-19 |
| Allogeneic Virus-specific T Cell Lines (VSTs) VSTs - Viral Infections After HSCT | Phase 1 | Completed | Catherine Bollard | 31 | 2014-10-28 | 2025-07-02 |
| Multivirus-specific Cytotoxic T Lymphocytes (mCTL) mCTLs - Refractory Viral Infections | Phase 1 | Completed | Catherine Bollard | 1 | 2014-04-01 | 2020-01-18 |
| Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) CTL for CMV seropositive donors, CTL for CMV naïve donors - EBV, CMV | Phase 1 | Completed | Catherine Bollard | 27 | 2014-02-01 | 2025-07-03 |
| Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma LMP1/2 CTLs (Group A), LMP1/2 CTLs (Group B) - Hodgkin Disease, Non Hodgkin Lymphoma | Phase 1 | Completed | Catherine Bollard | 10 | 2013-11-01 | 2024-12-19 |
Hodgkin Disease (2) · Virus Diseases (2) · Adenoviridae Infections (1) · Brain Neoplasms (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · HIV Infections (1) · Heart Defects, Congenital (1) · Hematologic Neoplasms (1) · Inflammatory Bowel Diseases (1) · Leiomyosarcoma (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1)
Bone Marrow Transplantation (1) · Nivolumab (1) · Sirolimus (1)
United States (14)
Michael Keller, MD (2) · Boyu Hu, MD (1) · Eugene Hwang, MD (1) · Laurie S. Conklin, M.D. (1) · Richard Ambinder, MD, PhD (1) · Richard Jonas, MD (1) · Steve Devine, MD, MS (1)
PMID 30262660, PMID 31219185, PMID 34495306, PMID 35244681, PMID 36240296, PMID 42380677
U10HL069294 (1)